



HLS Therapeutics®

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that the annual meeting (the “**Meeting**”) of the holders (“**Shareholders**”) of common shares (“**Common Shares**”) of HLS Therapeutics Inc. (the “**Company**”) will be held at the offices of Blake, Cassels & Graydon LLP, 199 Bay Street, Commerce Court West, Suite 4000, Toronto, Ontario M5L 1A9, on Friday June 22, 2018 at 10:00 a.m. (Toronto time) for the following purposes:

- (a) to receive the audited consolidated financial statements of each of HLS Therapeutics Inc. and Automodular Corporation, the predecessor corporations to the Company, in each case as at and for the year ended December 31, 2017, together with the auditors’ reports thereon;
- (b) to elect directors of the Company for the ensuing year;
- (c) to appoint auditors of the Company for the ensuing year and authorize the directors of the Company to fix such auditors’ remuneration;
- (d) to consider and, if thought advisable, to pass, with or without variation, an ordinary resolution, the full text of which is set out in Schedule A of the accompanying management information circular (the “**Circular**”), approving the Amended and Restated Stock Option Plan of the Company; and
- (e) to transact such other business as may properly be brought before the Meeting or any adjournment(s) thereof.

The accompanying Circular provides additional information relating to the matters to be dealt with at the Meeting. The directors of the Company have fixed May 18, 2018 as the record date for determining those Shareholders entitled to receive notice of and vote at the Meeting. The directors of the Company have fixed May 18, 2018 as the record date for determining those holders of Class A preferred shares of the Company (“**Preferred Shares**”) entitled to receive notice of and attend the Meeting. Holders of Preferred Shares are not entitled to vote at the Meeting.

If you are a registered Shareholder (i.e., you hold a physical certificate representing your Common Shares in your name) and are unable to attend the Meeting in person, please exercise your right to vote by dating, signing and returning the accompanying form of proxy to Computershare Investor Services Inc., the Company’s transfer agent. **You may also vote your Common Shares by proxy by appointing another person to attend the Meeting and vote your Common Shares for you.** To be valid, completed proxy forms must be dated, completed, signed and deposited with Computershare Investor Services Inc., (i) by mail using the enclosed return envelope or one addressed to Computershare Investor Services Inc., 100 University Avenue, 8th Floor, Toronto, Ontario, M5J 2Y1 Attn: Proxy Department, (ii) by facsimile to 1-866-249-7775, (iii) on the internet at www.investorvote.com, or (iv) instructions must be received by phone at 1-866-732-8683, in each case no later than 10:00 a.m. (Toronto time) on June 20, 2018 or, if the Meeting is adjourned or postponed, not less than 48 hours (excluding Saturdays, Sundays and statutory holidays in Toronto, Ontario) before any adjournment or postponement of the Meeting.

If you are a non-registered Shareholder and have received these materials from your broker or another intermediary, please complete and return the voting instruction form or other authorization form provided to you by your broker or intermediary in accordance with the instructions provided. Failure to do so may result in your Common Shares not being eligible to be voted at the Meeting.

Dated at Toronto, Ontario, this 24th day of May, 2018.

BY ORDER OF THE BOARD OF DIRECTORS OF HLS THERAPEUTICS INC.

“Ryan C. Lennox”

RYAN C. LENNOX
Corporate Secretary and General Counsel